Wuhan Kangfude Biotechnology Co., Ltd.

Nexttobe Ab

Xiaofeng Wang

Wei Wang

Haifeng Liu

Xianqiao Chen

Huoqing Chen

Yi Wang

Baoping Song

Pei Tong

Yanhong Liu

He Huang

The present invention relates to a recombinant OxDC expressed in a filamentous fungal host cell, methods for constructing a recombinant filamentous fungal host cell, methods for producing recombinant OxDC and the application thereof. The recombinant filamentous fungal host cell comprises one or more copies of OxDC expression cassette integrated in its genome; the expression cassette comprises a promoter, a signal peptide coding sequence, an OxDC coding sequence and a transcription terminator. The host cell can be constructed by random integration or site-specific integration. In addition, the present invention also optimizes the medium formulation for different recombinant filamentous fungal host cells. In the production of the recombinant OxDC, the final yield and enzyme activity were greatly improved. The invention effectively solves the problem that the production of OxDC in the prior art cannot be industrialized on a large scale.

Recombinant oxalate decarboxylase expressed in filamentous fungi

The present invention discloses a glycosylated oxalate decarboxylase. The oxalate decarboxylase is derived from edible basidiomycetes, the glycosylated oxalate decarboxylase has an enzyme activity at the pH value of 1.5-7.5, the activity at the pH value of 1.5-2.0 is 10% greater than the optimum activity, and a specific activity is more than 2 U/mg. The present invention also discloses preparation and application of the glycosylated oxalate decarboxylase. The glycosylated oxalate decarboxylase disclosed by the present invention can keep the activity under a low pH value, and can effectively prevent and treat kidney stones.

Glycosylated oxalate decarboxylase and preparation and application thereof

Novel oxalate oxidases are provided, which have suitable oxalate degrading activity near physiological pH (7.4). The properties of these OxOx make them potential drug candidates for use in reducing oxalate concentration in patients suffering from excess of oxalate. Especially due to the high activity at physiological pH, the OxOx's are suitable drug candidates for parenteral administration, i.e. to reduce the oxalate concentration in the plasma.

Methods of treatment using recombinant oxalate oxidase

Growing community of inventors

Wuhan, China

Xiaofeng Wang